Next-generation pneumococcal conjugate vaccine development for LMICs
Inventprise is developing efficacious, affordable vaccines for global populations most in need. The foundation’s support is helping Inventprise advance the novel pneumococcal conjugate vaccine (IVT-25), which will be made available, accessible, and affordable to low- and middle-income countries. Inventprise will also make its platform available for future vaccine development.
-
Domain
-
Investment typeDirect equity
-
StatusActive
-
Initial investmentSeed
-
Partnered in2021
-
Investment leadRichard Holmes
-
HeadquartersUSA
-
Program strategyPneumonia
More about our work
Our focus
Our six domains of focus comprise 40+ program strategies across the Foundation’s nearly $9B annual charitable support.
Investment approach
Fostering partnerships with the private sector to leverage groundbreaking global innovations for societal good.
Our team
We bring depth of experience to every investment, with a proven track record across sectors and scale.